GARS1 and schizophrenia: Repeated findings from animal models suggest that compounds that elevate brain glycine levels may be implicated for the treatment of AUD and schizophrenia, targeting preferentially GlyRs in the nAc or the co-agonist site on NMDA-Rs in the prefrontal cortex and hippocampus, respectively (Balu 2016, Soderpalm et al. 2017).